While most players have been lining up to develop autologous chimeric antigen receptor T cell therapies, Pfizer Inc. has chosen to partner with Cellectis S.A. to develop an allogeneic product that is intended for off-the-shelf use in any patient.

Pfizer has exclusive rights to develop and commercialize CAR T therapies for 15 oncology targets that it selects. Cellectis received $80 million up front and could receive up to $185 million in milestones per Pfizer product, plus tiered royalties. The pharma also will purchase a 10% stake in the biotech at €9.25 per share.